1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
NIH, CDC, and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) is sponsored by National Institutes of Health (NIH) / National Cancer Institute (NCI). This parent announcement covers investigator-initiated small business projects, supporting the preclinical development, small molecule lead optimization, synthesis, and evaluation of targeted oncology therapeutics—including antibody-drug conjugates (ADCs) and novel payload optimization—within the research mission of the National Cancer Institute.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: For-profit U.S. small business concerns (500 or fewer employees, independently owned and operated). Confirm the full requirements in the official notice before applying.
The current listing shows phase I awards typically up to $400,000 for 1 year; Phase II awards up to $2,250,000 for 2 years. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for NIH, CDC, and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) are due January 5, 2027. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
NIH, CDC, and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) is funded by National Institutes of Health (NIH) / National Cancer Institute (NCI). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
PAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read articleNIH's RFI on administrative burden (NOT-OD-26-118) takes comments through December 8, 2026. It asks seven questions, lists eight reforms already made, and warns that responses may be posted unredacted. Here is what NIH is really asking for, what it can and cannot change alone, and how researchers and research offices should respond.
Read articleOn November 2, 2026, NIH released NOT-OD-27-006, a draft update to its Policy for Data and Safety Monitoring. As summarized by Harvard's research integrity office, the draft would extend risk-based monitoring from clinical trials to all NIH-supported clinical research, drop the blanket DSMB requirement for Phase 3 and multi-site trials, and require an NIH-approved monitoring plan scaled to risk, effective for applications six months after the final policy. Comments are due January 6, 2027. What it changes and how to respond.
Read article